Frequency of symptomatic adverse events in rheumatoid arthritis: an exploratory online survey

Glen S. Hazlewood^{1,2,3} (<https://orcid.org/0000-0001-7709-3741>), Orit Schieir⁴ (<https://orcid.org/0000-0002-5217-9028>), Vivian Bykerk⁵, Kamso Mujaab², Peter Tugwell^{6,7}, George Wells⁸, Dawn Richards⁹, Laurie Proulx⁹ (<https://orcid.org/0000-0003-1656-0371>), Pauline M. Hull² (<https://orcid.org/0000-0002-2954-6811>), Susan J. Bartlett^{3,10,11} (<https://orcid.org/0000-0001-9755-2490>)

Key indexing terms (MeSH): adverse effects, drug-related side effects and adverse reactions, rheumatoid arthritis, patient reported outcome measures, antirheumatic agents

Name of Departments and Institutions to which the work should be attributed:

¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

²Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada

³Arthritis Research Canada, Richmond, BC, Canada

⁴Canadian Early Arthritis Cohort Study, Toronto, Ontario, Canada

⁵Hospital for Special Surgery, Weill Cornell Medical College, New York New York, USA

⁶Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

⁷Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

⁸Cardiovascular Research Methods Centre, Ottawa Heart Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada

⁹Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada

¹⁰Department of Medicine, McGill University, Montreal, Quebec, Canada

¹¹Research Institute-McGill University Health Center, McGill University, Montreal, Quebec, Canada

Funding: Dr. Hazlewood is supported by a Canadian Institutes of Health Research New Investigator Award. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) [FRN 156267].

Conflicts of interest:

GS Hazlewood: None

O Schieir: None

V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding:

Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB

K Mujaab: None

P Tugwell: None

G Wells: None

D Richards: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies.

Consulting fees: NovoNordisk Canada (Speaking about arthritis advocacy); Eli Lilly Canada (Speaking about living with rheumatoid arthritis and participating in an advisory board)

L Proulx: Volunteer Vice President of the Canadian Arthritis Patient Alliance, an organization that receives the majority of its funding from independent grants from pharma companies.

Consulting fees: Eli Lilly Canada (sharing patient perspectives at an event).

P Hull: None

SJ Bartlett: Honoria: Organon, Janssen, Pfizer,

Initials, surnames, appointments, and highest academic degrees of all authors:

GS Hazlewood, MD PhD, Associate Professor

O Schieir, PhD

V Bykerk, MD, Professor

K Mujaab, MSc

P Tugwell, MD, Professor

G Wells, PhD, Professor

DP Richards, PhD

L Proulx, B.Com

PM Hull, PGCE PGDip (BJTC)

SJ Bartlett, PhD, Professor

Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca

Running title: Symptomatic AE in RA

Accepted Article

Word count: 2922

This accepted article is protected by copyright. All rights reserved.

ABSTRACT

Objective: To generate initial data on the frequency and impact of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patients' perspective.

Methods: We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes version of The Common Terminology Criteria For Adverse Events (PRO-CTCAE™). Results were summarized to report their frequency and regression models were used to estimate their associations with RA medication use and overall bother.

Results: The 560 patients who completed the survey and reported taking at least one RA medication (DMARD, steroids, NSAIDs), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1-10 (28%), 11-20 (28%), and >20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%) or very much (15%). In multi-variable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22 respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles.

Conclusion: In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease.

INTRODUCTION

People with rheumatic diseases typically require life-long treatment. When deciding whether and how much of their medication to take, people weigh the benefits against the impact of their medications on their life (1). Patients commonly list symptomatic adverse events (AEs) or side effects as key reasons when choosing to take less medication (2). People also learn to adjust their lives to manage the symptomatic AEs they experience, and the cumulative burden of these may have a considerable impact on quality of life over time (1).

In clinical trials for rheumatic diseases, adverse events are typically graded using the Common Terminology for Adverse Events (CTCAE) (3) or the Rheumatology Common Toxicity Criteria (RCTC) (4). These approaches rely on reporting from physicians and/or trained research personnel, but do not capture information on bothersome side effects from the perspective of patients (5). In oncology, the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™, <https://healthcaredelivery.cancer.gov/pro-ctcae/>) (6) has been developed to allow patients to self-report the presence, absence, frequency, severity and interference from an item bank of 80 symptomatic AEs for patients in cancer clinical trials. It was developed with patient involvement using rigorous qualitative and quantitative methods and has been extensively validated in 30 languages (7). Investigators can select subsets of symptomatic AEs from the item library, as relevant for their purpose, depending on the disease and treatments being studied. The intention is not to replace the CTCAE, but rather to provide a patient-reported measure to complement existing drug safety information (6).

The objectives of this study were to describe the frequency of symptomatic AEs listed in the PRO-CTCAE™ item library in patients with RA, identify important items not currently included, and evaluate associations with RA medication use. While the PRO-CTCAE™ was developed for cancer trials, the extensive symptom library and overlapping medications (steroids, methotrexate, and injectable medications) provided a rationale for using it as a source for potential symptoms, with an overall aim to generate initial data that could be used to inform the future development of a rheumatology-specific instrument.

MATERIALS AND METHODS

Study design

We conducted a cross-sectional web-based survey for adults with self-identified RA to collect information on the frequency of symptomatic AEs (side effects; we use these terms interchangeably) from their RA medications. We did not administer the PRO-CTCAE, but rather used the PRO-CTCAE Quick Guide to the Item Library as a list of potential symptomatic AEs for our custom survey (6).

Survey development

The survey included questions about sociodemographics, current RA medication use and the complete list of 80 PRO-CTCAE™ symptomatic AEs, including free text fields asking patients to write in any other side effects they attributed to their RA medications (full survey in Supplementary Material). Patients were asked to indicate the presence/absence of each symptomatic AE (described as ‘side effects’ in the survey) experienced due to their rheumatoid

arthritis medication in the past 7 days and ever, respectively. They were also asked a single question at the end to indicate the extent to which they were “bothered by side effects of my rheumatoid arthritis medications” (1=“not at all” to 5=“very much”) (8). We chose to include the full list of symptoms in the PRO-CTCAE™ because it included a wide range of symptoms that encompassed most known side effect profiles. We had pilot tested giving the PRO-CTCAE domain list in earlier qualitative work with patients in Australia, US and Canada and received a very positive response from patients (1). Side effects that were clearly unrelated to RA medications ('radiation burns', 'bed sores') were not removed, but rather served as internal controls, where we would not expect any positive responses.

Administration & ethics

The 14-page online survey was hosted using Qualtrics survey software, and was approved by the University of Calgary Conjoint Research Ethics Board (REB# 18-0597). Participants viewed the consent form on the first page of the survey and implied consent was obtained on completion of the survey. Participants could go back to previous pages to change their answers. IP addresses were not recorded, but the survey software used cookies to prevent multiple responses from the same IP address. The survey was considered complete when they reached the last page. No incentives were provided.

Sample population

The survey sample initially included RA patients receiving treatment at an academic rheumatology clinic in Calgary, Alberta. However, in response to recruitment challenges during

the first wave of the COVID-19 pandemic, the web-based survey was advertised on social media through Canadian arthritis patient advocacy groups, inviting individuals to participate who were diagnosed with RA, receiving treatment from a rheumatologist, and using at least 1 RA treatment.

Patient and public involvement

Two patient partners (DR, LP) were involved throughout the study, including survey development, pre-testing, recruitment interpretation of findings and preparation of the manuscript. Additionally, the Arthritis Research Canada's Arthritis Patient Advisory Board reviewed the survey prior to dissemination and assisted with recruitment.

Data analysis

Descriptive statistics were used to summarize participant characteristics and the frequency of current and past side effects. We evaluated the overall bother of side-effects in relation to the number of side effects currently experienced (last 7 days) reported through Spearman's rank correlation, with overall bother as the dependent variable.

We explored the association between each of the 80 symptomatic AEs reported by patients in the last 7 days (dependent variable) and current RA medication use using multivariable logistic regression. Medications were categorized as: NSAIDs, prednisone, methotrexate, hydroxychloroquine, sulphasalazine, leflunomide, biologic DMARDs, and JAK inhibitors. Each of the 80 regression models included all eight medications/medication classes as independent

variables, and thereby evaluated the independent association with each RA medication/medication class. These analyses were viewed as exploratory, as causation cannot be inferred, given the cross-sectional nature of the survey. However, in a valid instrument of patient-reported side effects, we would expect to see some alignment between medication use and known side effect profiles. To prevent over-fitting, we limited the multivariable regression models to symptomatic AEs that were reported with a frequency of $\geq 15\%$. All analyses were conducted using R statistical software (version 3.6.1).

Sensitivity analyses

We identified respondents who reported taking implausible medication combinations (more than one advanced therapy; both oral and subcutaneous methotrexate), or reported either of two side effects that should not be associated with RA medications ('Skin burns from radiation' and 'Bed sores'). We recognized that some of these responses may be valid (e.g. patients may be switching between oral and subcutaneous methotrexate when they travel) or may reflect an error to that question and not the whole survey. Therefore, these patients were included for the main analyses, but were excluded in a sensitivity analysis for our regression analyses. Finally, we examined whether symptomatic AE differed by sex/gender where expected (e.g. vaginal dryness), again recognizing that while these symptomatic AEs could occur in patients with either self-reported gender, the frequency should be different.

RESULTS

Following the recruitment of 29 people in clinic in Calgary (23 of whom completed it), the survey was hosted online, where 913 people started the survey and 575 (63%) completed it. Of the 598 total people who completed the survey either in clinic or online, 560 (94%) reported taking at least one RA medication (NSAIDs or DMARDs including prednisone) and were included in this analysis. Demographics of the participants are presented in Table 1. Most were women (95%) and the mean age was 44. Participants were on a mean number of 6 total medications, of which 2 were for RA. NSAIDs were used by 56% and prednisone by 32% (21 and 3 patients respectively were using NSAIDs or prednisone alone with no other DMARDs). The most common conventional synthetic (cs)DMARD used was methotrexate (54%), split equally between oral and subcutaneous routes; other csDMARDs were less common (Table 1). Biologic DMARDs were used by 40% and JAK inhibitors by 11% (Table 1).

Frequency of symptomatic AEs

The number of symptomatic AEs participants reported experiencing in the past 7 days due to RA medicines ranged widely (see Supplementary Figure 1 for histogram of side effect frequency). Thirty-six participants (6%) reported no side effects, 71 (13%) reported between one and five, 82 (15%) between six and ten, 158 (28%) between 11 and 20, and 213 (38%) reported more than 20.

The frequency of each side-effect is presented in Figure 1. Of the 80 side effects, 45 (56%) were experienced in the past 7 days by $\geq 15\%$ of patients. Side effects with the highest frequency

included those that overlapped with common symptoms reported with RA disease (e.g. fatigue, aching joints), as well as typical side effects associated with medications (e.g. nausea, hair loss).

Overall 'bother' of symptomatic AEs attributed to RA medications

Thirty-nine percent of participants reported being bothered by side effects of their RA medications in the past 7 days "quite a bit" or "very much" (Table 2). Bother increased with the number of side effects reported (Table 2), although patients reporting they were 'not at all' bothered by their side effects, still reported a median of 8 symptomatic AEs.

Association between medication use and symptomatic AEs

Results for the multivariable models evaluating the association between medication use and the 45 symptomatic AEs with a frequency $\geq 15\%$ are presented in Tables 3 and 4 (symptomatic AEs with a statistically significant association are shown). Current prednisone had a statistically significant association with the greatest number of symptomatic AEs ($n=26$), followed by NSAIDs ($n=22$), sulphasalazine ($n=8$), methotrexate ($n=4$), JAK inhibitors ($n=4$), biologics ($n=2$) hydroxychloroquine ($n=2$). Leflunomide, which was only used by 72 participants, did not have a statistically significant association with any of the 45 symptomatic AEs evaluated. Many of the associations, particularly the ones with the largest effect sizes, aligned closely with known side-effect profiles of medications. Current use of methotrexate was associated with experiencing nausea, hair loss, difficulties with memory, and difficulties with concentration. Current hydroxychloroquine use was most strongly associated with sun sensitivity, and biologics with

easy bruising [worded as ‘bruise easily’ (black and blue marks)]. Current prednisone and NSAIDs use were associated with a wide range of side effects.

Sensitivity analyses

Of the 560 patients, 44 (8%) failed one or more of the tests of internal validity (taking both sc and oral methotrexate (n=18), taking more than 1 biologic (n=26), or reporting ‘bed sores’ (n=5) or ‘radiation burns’ (n=10) as side effects of their RA meds). When these patients were excluded from the analyses, the associations between medications and side-effects were largely the same (Supplementary Tables 2 and 3). A notable exception was an association between leflunomide and ‘numbness and tingling’ [OR, mean (95%CI); 1.15 (1.01-1.32)]; and ‘diarrhea’ [OR; 1.14 (1.01-1.30)]. Side effects showed expected associations with gender (Supplementary Table 3).

Free-text responses

Eighty-nine patients provided a total of 119 additional side effects they have attributed to their medications (ever) as a free-text response. Some (n=32) overlapped with items in the PRO-CTCAE™, and the remaining are summarized in Table 5. These included adverse events/diagnoses (e.g. cancer, diabetes) as well as additional symptomatic adverse events.

DISCUSSION

Our study suggests that real world patients using common RA treatment regimens report many symptomatic AEs they attribute to their RA medications. Collectively, these side effects are substantially bothersome to many patients. Taken together, this exploratory study suggests a potentially large, underrecognized burden of symptomatic AEs that people with RA attribute to their RA medications. While the cross-sectional nature of our study prevents causal inference, the associations observed between current medication use and side-effects in the past 7 days found many expected side-effects. This supports the importance of collecting side effect reports directly from patients. Further work is required to develop an RA or rheumatology-specific instrument.

For this work, we utilized all symptoms contained in the PRO-CTCAE™ symptom item bank (6). Importantly, the PRO-CTCAE™ was developed to collect symptomatic AEs in oncology clinical trials. However, several aspects make it appealing as an initial list to build from for a rheumatology specific inventory. It offers a reasonably comprehensive list that covers most common medication-related symptoms patients experience. While two side effects are clearly unrelated to RA meds (e.g., 'radiation burns', 'bed sores'), we decided to include the full list of side effects as they provided additional checks of internal validity. These could be removed from an RA-specific instrument, as could others that may not be relevant to RA medications. Importantly, the free-text responses also highlighted potential missing side effects such as 'brain fog', 'dry eyes', 'mood swings', and others that respondents attributed to their RA medicines. Additional work is needed to clarify the range of side effects that are important to

patients that should be routinely collected in people with RA and other rheumatic diseases. Including patients in this process will be essential.

Strengths of our study include collecting side effects directly from the patient, the relatively large sample size, and including patients as research partners throughout the process, from study design to interpreting results. While our study was cross-sectional and cannot therefore evaluate causation, many of the strongest associations observed were in line with expected side-effects. We found a large number of side-effects associated with prednisone and NSAID use. Some of these likely reflect the true burden of side-effects, which are common with both NSAIDs and prednisone in rheumatic diseases (9,10). Prior work has found patients and physicians place different importance on adverse effects from glucocorticoid use,(11) so patient-reported collection of side effects may supplement the routine monitoring of adverse events, which has been recommended for patients taking glucocorticoids, even at low doses(12). Some of these side effects, however, may be related to active RA, as patients taking NSAIDs or prednisone are more likely to have active (or recently active) disease. While we asked patients to indicate which side effects they had experienced “as a result of your rheumatoid arthritis medications”, assigning attribution of symptoms is challenging (13,14). Understanding attribution would need to occur through longitudinal or and/or interventional studies. Regardless, this highlights the importance of understanding patient-reported side effects; a high perceived burden of symptomatic side effects may shift the risk/benefit balance when patients decide to reduce or stop a medication (15).

Our study has limitations. We recruited patients online, so it was not possible to know how many people viewed the invitation or calculate a response rate. It is possible there was a self-selection bias with patients experiencing more side effects more likely to respond to the survey. We had no information about disease activity or other clinical data, including comorbidities and other non-RA medications, which would have provided more context to the findings. Few men completed the survey and owing to the method of collection, and our sample is largely limited to computer literate patients who are active members of online patient groups. Future research would benefit from targeting the specific experiences of older and male patients, perhaps through in clinic recruitment with both paper-based and electronic methods of data collection. We did not include a measure of severity for each side-effect as we were concerned about question fatigue with an online survey, so are unable to determine which side effects were the most bothersome. We did include a single-response item of overall medication 'bother' (8), which showed a strong correlation with the number of side effects, and support its use as a global measure of impact or bother. Adding a measure of severity or bother for each side-effect is clearly needed to understand the burden associated with specific RA medications. In our study, patients who reported they were 'not at all bothered' by side effects still reported a median of 8 side effects.

How to best measure side effects is controversial. Non-specific symptoms that are generally not serious are common in placebo recipients in clinical trials (16) and 75%-90% of the general adult population report at least one symptom at any given time, similar to rates observed in our study (17,18). Checklists of side-effects have been shown to result in many more side effects

being reported than open-ended elicitation and may therefore lead to over-reporting (19,20). However, patients have been shown to under-report side-effects to clinicians, and this underreporting can result in preventable adverse events (5,21,22). Open-ended questioning by a trained research assistant, with subsequent mapping to common terminology (e.g. CTCTAE(3) or Medical Dictionary for Regulatory Activities (MedDRA)(23)), is the standard in regulatory clinical trials. However, this can be challenging to implement in clinical studies and in practice. Another option is free-form unstructured reporting by patients, by keeping a diary for example. Traditionally, this method has posed challenges, but with the advent of phone App technology and push notifications, real-time collection of patient-reported outcomes through electronic diaries has shown promise (24). Including some measure of side effect ('bother' or 'burden') for each side-effect, and allowing free-text additions may also help mitigate the limitations of a checklist, and support patients and clinicians in having an informed discussion about which side effects are having the most life impact.

In summary, our results show the promise of a patient-reported inventory of side effects for patients with RA. Our results suggest the frequency and burden of side-effects in RA medicines merits further study. Next steps from this work would be to identify a prioritized candidate list of side effect domains with further input from patients and clinicians, and evaluate the optimal way to ask about side effect severity/burden in trials. Broader input is needed from international patients and other rheumatic diseases (25). The instrument would then need to be validated through longitudinal or interventional studies, while also capturing data on

medication use and adherence, disease-related measures (e.g. disease activity and duration), comorbidities and other potential confounding variables.

ACKNOWLEDGEMENTS

The authors thank the Canadian Arthritis Patient Alliance (CAPA) and Arthritis Research Canada's Arthritis Patient Advisory Board for assistance in reviewing the survey and recruiting patients for the study.

REFERENCES

1. Andersen KM, Kelly A, Lyddiatt A, et al. Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. *J Rheumatol* 2019;46:1168-72.
2. Hope HF, Hyrich KL, Anderson J, et al. The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. *Rheumatology (Oxford)* 2020;59:213-23.
3. National Cancer Institute (US). Common terminology criteria for adverse events: (CTCAE). (Epub ahead of print).
4. Stach CM, Sloan VS, Woodworth TG, Kilgallen B, Furst DE. Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use. *Drug Saf* 2019;42:1499-506.
5. Basch E. The missing voice of patients in drug-safety reporting. *N Engl J Med* 2010;362:865-9.
6. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst* 2014;106.
7. Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Am Soc Clin Oncol Educ Book* 2016;35:67-73.
8. Pearman TP, Beaumont JL, Mroczek D, O'Connor M, Cella D. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. *Cancer* 2018;124:991-7.
9. Black RJ, Robson JC, Goodman SM, et al. A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. *J Rheumatol* 2017;44:1754-8.
10. Crofford LJ. Use of NSAIDs in treating patients with arthritis. *Arthritis Res Ther* 2013;15 Suppl 3:S2.
11. van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis* 2010;69:1015-21.

12. van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. *Ann Rheum Dis* 2010;69:1913-9.
13. Le-Rademacher JG, Storrick EM, Jatoi A, Mandrekar SJ. Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials. *Mayo Clin Proc Innov Qual Outcomes* 2019;3:176-82.
14. Hillman SL, Mandrekar SJ, Bot B, et al. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. *J Clin Oncol* 2010;28:3002-7.
15. Andersen KM, Cheah JTL, March L, et al. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. *J Rheumatol* 2019;46:1053-8.
16. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the placebo phenomenon. *JAMA* 2002;287:622-7.
17. Petrie KJ, Faasse K, Crichton F, Grey A. How common are symptoms? Evidence from a New Zealand national telephone survey. *BMJ Open* 2014;4:e005374.
18. Eriksen H, Svendsrod R, Ursin G, Ursin H. Prevalence of subjective health complaints in the Nordic European countries in 1993. *European Journal of Public Health* 1998;8:294-8.
19. Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. *Ann Intern Med* 2006;144:257-61.
20. Ioannidis JP, Mulrow CD, Goodman SN. Adverse events: the more you search, the more you find. *Ann Intern Med* 2006;144:298-300.
21. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. *J Natl Cancer Inst* 2009;101:1624-32.
22. Weingart SN, Gandhi TK, Seger AC, et al. Patient-reported medication symptoms in primary care. *Arch Intern Med* 2005;165:234-40.
23. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). *Drug Saf* 1999;20:109-17.
24. Bingham CO, 3rd, Gaich CL, DeLozier AM, et al. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. *Trials* 2019;20:182.

25. Berthelsen DB, Woodworth TG, Goel N, et al. Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. *Semin Arthritis Rheum* 2021;51:607-17.

FIGURE LEGENDS

Figure 1. Frequency of symptomatic adverse events in patients with rheumatoid arthritis. The vertical line indicates a frequency of 15%.

Table 1. Patient characteristics

Characteristic	Value (N=560)
Age, mean (SD)	44.3 (12.6), missing = 72
Gender, n (%)	
Female	530 (95)
Male	28 (5)
Diverse	1 (<1)
Prefer not to answer	1 (<1)
Disease duration	
Total years, mean (SD)	8.1 (9.7)
<2 years, n (%)	144 (26)
2 to <5 years, n (%)	151 (27)
5 to <10 years, n (%)	96 (17)
>=10 years, n (%)	169 (30)
Total number of medications, including non-RA meds, mean (SD)	5.9 (3.7), missing = 1
Total number of RA medications, mean (SD)	1.7 (1.0)
Current RA medications, n (%)	
NSAIDs	316 (56)
Prednisone	181 (32)
Methotrexate	300 (54)
-oral	185 (33)*
-subcutaneous	133 (24)*

Hydroxychloroquine	218 (39)
Sulphasalazine	97 (17)
Leflunomide	72 (13)
Biologic DMARD	226 (40)
JAK inhibitor	60 (11)

*18 people reported being on both oral and subcutaneous methotrexate

Table 2. Overall bother of RA medication symptomatic AEs (past 7 days)

	Not at all	A little bit	Somewhat	Quite a bit	Very much
N (%)	65 (12%)	117 (21%)	159 (28%)	137 (24%)	82 (15%)
Median (Q1, Q3) number of side effects*	8 (2, 20)	12 (6, 18)	15 (8, 24)	21 (12, 28)	24 (17, 35)

*Spearman rank-correlation 0.35 ($P < 0.001$) for a trend across ordered groups; abbreviations:

Q1, 25th percentile; Q3, 75th percentile

Table 3. Multivariable association between medication use and odds of symptomatic AEs: conventional, biologic and targeted synthetic DMARDs

Methotrexate (n=300)		Hydroxychloroquine (n=218)		Sulphasalazine (n=97)		Biologic DMARD (n=226)		JAK (n=60)	
Nausea	1.18 (1.09-1.28)	Sun sensitivity	1.17 (1.08-1.28)	Nothing could cheer up	1.18 (1.07-1.30)	Bruise easily	1.17 (1.08-1.27)	Dry mouth	1.19 (1.04-1.36)
Concentration	1.10 (1.02-1.20)	Gas	1.10 (1.01-1.19)	Sad	1.16 (1.04-1.29)	Itchiness	1.09 (1.01-1.18)	Acne	1.19 (1.06-1.32)
Memory	1.10 (1.02-1.20)	Nothing could cheer up	0.92 (0.85-0.99)*	Insomnia	1.13 (1.02-1.27)	Dizziness	0.89 (0.82-0.96)*	Diarrhea	1.15 (1.01-1.30)
Hair loss	1.09 (1.01-1.19)	Sad	0.90 (0.83-0.98)*	Watery eyes	1.13 (1.02-1.24)			Hoarseness	1.12 (1.01-1.24)
				Dry mouth	1.12 (1.00-1.25)				
				Decreased sexual interest	1.11 (1.01-1.23)				
				Shortness of breath	1.10 (1.01-1.21)				

Chills	1.09 (1.01-1.19)
--------	------------------

Side effects with frequency 15% and statistically significant association.
*denotes medication use was associated with a lower odds of reporting the side effect.

Table 4. Multivariable association between medication use and odds of symptomatic AEs:

NSAIDs and prednisone

NSAIDs (n=316)		Prednisone (n=181)	
Pain	1.25 (1.16-1.36)	Headache	1.18 (1.08-1.29)
Aching muscles	1.24 (1.14-1.34)	Increased sweating	1.17 (1.07-1.27)
Aching joints	1.19 (1.10-1.29)	Constipation	1.17 (1.08-1.27)
Headache	1.15 (1.06-1.25)	Pain	1.16 (1.07-1.27)
Anxiety	1.15 (1.06-1.25)	Aching joints	1.15 (1.06-1.26)
Insomnia	1.13 (1.04-1.23)	Palpitations	1.15 (1.07-1.24)
Concentration	1.13 (1.04-1.23)	Abdominal pain	1.15 (1.06-1.25)
Fatigue	1.12 (1.05-1.21)	Fatigue	1.14 (1.06-1.23)
Numbness & tingling	1.11 (1.03-1.21)	Sad	1.14 (1.04-1.24)
Constipation	1.11 (1.03-1.20)	Arm/leg swelling	1.14 (1.06-1.22)
Memory	1.11 (1.02-1.21)	Anxiety	1.14 (1.04-1.24)
Urinary frequency	1.10 (1.03-1.18)	Memory	1.13 (1.04-1.24)
Itchiness	1.10 (1.02-1.19)	Bruise easily	1.13 (1.04-1.24)
Abdo pain	1.10 (1.02-1.19)	Bloating	1.13 (1.03-1.23)
		Nothing could cheer	
Gas	1.10 (1.02-1.19)	up	1.13 (1.04-1.22)
Arm/leg swelling	1.10 (1.03-1.17)	Hoarseness	1.12 (1.05-1.20)
Chills	1.10 (1.03-1.17)	Blurred vision	1.12 (1.04-1.21)

Sad	1.09 (1.01-1.18)	Hot flashes	1.12 (1.04-1.20)
Hot flashes	1.09 (1.02-1.17)	Decreased appetite	1.12 (1.04-1.20)
Urinary urgency	1.09 (1.03-1.15)	Insomnia	1.12 (1.02-1.22)
Nausea	1.09 (1.00-1.18)	Numbness & tingling	1.11 (1.01-1.21)
Bloating	1.09 (1.00-1.18)	Concentration	1.10 (1.01-1.20)
		Decreased sexual	
		interest	1.09 (1.01-1.19)
		Sun sensitivity	1.09 (1.00-1.19)
		Shortness of breath	1.09 (1.01-1.17)
		Visual floaters	1.07 (1.00-1.15)

*Side effects with frequency (15%) and statistically significant association reported

Table 5. Additional symptomatic AEs provided by participants not captured in PRO-CTCAE

Side effect	N
Infections or infectious symptoms (e.g. sinus infection/ congestion, urinary tract infections)	13
Change in weight (gain or loss) or appetite	12
Other adverse events (e.g. TIA, NSIP, neuropathy, cancer, diabetes, osteoporosis)	9
Dry eyes	7
Other cutaneous (e.g. skin lightening, water pimples/blisters, skin necrosis)	7
Brain fog / feeling slow or lethargic/clumsy/ditzy	7
Other neurological (e.g. tremors, muscle weakness, muscle cramping, visual disturbance)	6
Other mood (e.g. mood swings, irritability, panic attacks)	4
Temperature fluctuations/sensitivity (e.g. fever, hot/cold sensitivity)	4
Allergy	3
Other cardio/metabolic (e.g. blood pressure, lipid changes)	2